Kiniksa Pharmaceuticals International (KNSA) Leases: 2021-2025
Historic Leases for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $10.1 million.
- Kiniksa Pharmaceuticals International's Leases fell 9.21% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year decrease of 9.21%. This contributed to the annual value of $10.4 million for FY2024, which is 13.03% down from last year.
- Kiniksa Pharmaceuticals International's Leases amounted to $10.1 million in Q3 2025, which was down 2.24% from $10.3 million recorded in Q2 2025.
- In the past 5 years, Kiniksa Pharmaceuticals International's Leases registered a high of $13.2 million during Q2 2023, and its lowest value of $4.1 million during Q2 2022.
- Its 3-year average for Leases is $10.9 million, with a median of $11.1 million in 2024.
- Per our database at Business Quant, Kiniksa Pharmaceuticals International's Leases fell by 24.45% in 2022 and then spiked by 224.18% in 2023.
- Quarterly analysis of 5 years shows Kiniksa Pharmaceuticals International's Leases stood at $5.5 million in 2021, then fell by 2.97% to $5.4 million in 2022, then skyrocketed by 121.56% to $11.9 million in 2023, then decreased by 13.03% to $10.4 million in 2024, then decreased by 9.21% to $10.1 million in 2025.
- Its Leases stands at $10.1 million for Q3 2025, versus $10.3 million for Q2 2025 and $10.5 million for Q1 2025.